{"version":"6.9","hitCount":1,"request":{"queryString":"ext_id:37364590 AND src:med","internalQuery":"ext_id:37364590 AND src:med","resultType":"CORE","cursorMark":"*","pageSize":25,"sort":"","synonym":false},"resultList":{"result":[{"id":"37364590","source":"MED","pmid":"37364590","doi":"10.1016/s0140-6736(23)01163-7","title":"Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.","authorString":"Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M.","authorList":{"author":[{"fullName":"Frias JP","lastName":"Frias","firstName":"Juan P","initials":"JP","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Velocity Clinical Research, Los Angeles, CA, USA. Electronic address: jfrias@velocityclinical.com."}]}},{"fullName":"Deenadayalan S","lastName":"Deenadayalan","firstName":"Srikanth","initials":"S","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Novo Nordisk, Søborg, Denmark."}]}},{"fullName":"Erichsen L","lastName":"Erichsen","firstName":"Lars","initials":"L","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Novo Nordisk, Søborg, Denmark."}]}},{"fullName":"Knop FK","lastName":"Knop","firstName":"Filip K","initials":"FK","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Steno Diabetes Center Copenhagen, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark."}]}},{"fullName":"Lingvay I","lastName":"Lingvay","firstName":"Ildiko","initials":"I","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Division of Endocrinology, Department of Internal Medicine and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA."}]}},{"fullName":"Macura S","lastName":"Macura","firstName":"Stanislava","initials":"S","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Novo Nordisk, Søborg, Denmark."}]}},{"fullName":"Mathieu C","lastName":"Mathieu","firstName":"Chantal","initials":"C","authorId":{"type":"ORCID","value":"0000-0002-4055-5233"},"authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Clinical and Experimental Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium."}]}},{"fullName":"Pedersen SD","lastName":"Pedersen","firstName":"Sue D","initials":"SD","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"C-ENDO Diabetes and Endocrinology Clinic, Calgary, AB, Canada."}]}},{"fullName":"Davies M","lastName":"Davies","firstName":"Melanie","initials":"M","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"Diabetes Research Centre, University of Leicester, Leicester, UK; Leicester NIHR Biomedical Research Centre, Leicester General Hospital, Leicester, UK."}]}}]},"authorIdList":{"authorId":[{"type":"ORCID","value":"0000-0002-4055-5233"}]},"dataLinksTagsList":{"dataLinkstag":["altmetrics","supporting_data"]},"journalInfo":{"issue":"10403","volume":"402","journalIssueId":3621952,"dateOfPublication":"2023 Aug","monthOfPublication":8,"yearOfPublication":2023,"journal":{"medlineAbbreviation":"Lancet","title":"Lancet (London, England)","essn":"1474-547X","issn":"0140-6736","isoabbreviation":"Lancet","nlmid":"2985213R"},"printPublicationDate":"2023-08-01"},"pubYear":"2023","pageInfo":"720-730","abstractText":"<h4>Background</h4>Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA<sub>1c</sub>) is unknown. This trial assessed the efficacy and safety of co-administered semaglutide with cagrilintide (CagriSema) in participants with type 2 diabetes.<h4>Methods</h4>This 32-week, multicentre, double-blind, phase 2 trial was conducted across 17 sites in the USA. Adults with type 2 diabetes and a BMI of 27 kg/m<sup>2</sup> or higher on metformin with or without an SGLT2 inhibitor were randomly assigned (1:1:1) to once-weekly subcutaneous CagriSema, semaglutide, or cagrilintide (all escalated to 2·4 mg). Randomisation was done centrally using an interactive web response system and was stratified according to use of SGLT2 inhibitor treatment (yes vs no). The trial participants, investigators, and trial sponsor staff were masked to treatment assignment throughout the trial. The primary endpoint was change from baseline in HbA<sub>1c</sub>; secondary endpoints were bodyweight, fasting plasma glucose, continuous glucose monitoring (CGM) parameters, and safety. Efficacy analyses were performed in all participants who had undergone randomisation, and safety analyses in all participants who had undergone randomisation and received at least one dose of the trial medication. This trial is registered on ClinicalTrials.gov (NCT04982575) and is complete.<h4>Findings</h4>Between Aug 2 and Oct 18, 2021, 92 participants were randomly assigned to CagriSema (n=31), semaglutide (n=31), or cagrilintide (n=30). 59 (64%) participants were male; the mean age of participants was 58 years (SD 9). The mean change in HbA<sub>1c</sub> from baseline to week 32 (CagriSema: -2·2 percentage points [SE 0·15]; semaglutide: -1·8 percentage points [0·16]; cagrilintide: -0·9 percentage points [0·15]) was greater with CagriSema versus cagrilintide (estimated treatment difference -1·3 percentage points [95% CI -1·7 to -0·8]; p<0·0001), but not versus semaglutide (-0·4 percentage points [-0·8 to 0·0]; p=0·075). The mean change in bodyweight from baseline to week 32 (CagriSema: -15·6% [SE 1·26]; semaglutide: -5·1% [1·26]; cagrilintide: -8·1% [1·23]) was greater with CagriSema versus both semaglutide (p<0·0001) and cagrilintide (p<0·0001). The mean change in fasting plasma glucose from baseline to week 32 (CagriSema: -3·3 mmol/L [SE 0·3]; semaglutide: -2·5 mmol/L [0·4]; cagrilintide: -1·7 mmol/L [0·3]) was greater with CagriSema versus cagrilintide (p=0·0010) but not versus semaglutide (p=0·10). Time in range (3·9-10·0 mmol/L) was 45·9%, 32·6%, and 56·9% at baseline and 88·9%, 76·2%, and 71·7% at week 32 with CagriSema, semaglutide, and cagrilintide, respectively. Adverse events were reported by 21 (68%) participants in the CagriSema group, 22 (71%) in the semaglutide group, and 24 (80%) in the cagrilintide group. Mild or moderate gastrointestinal adverse events were most common; no level 2 or 3 hypoglycaemia was reported. No fatal adverse events were reported.<h4>Interpretation</h4>In people with type 2 diabetes, treatment with CagriSema resulted in clinically relevant improvements in glycaemic control (including CGM parameters). The mean change in HbA<sub>1c</sub> with CagriSema was greater versus cagrilintide, but not versus semaglutide. Treatment with CagriSema resulted in significantly greater weight loss versus semaglutide and cagrilintide and was well tolerated. These data support further investigation of CagriSema in this population in longer and larger phase 3 studies.<h4>Funding</h4>Novo Nordisk.","affiliation":"Velocity Clinical Research, Los Angeles, CA, USA. Electronic address: jfrias@velocityclinical.com.","publicationStatus":"ppublish","language":"eng","pubModel":"Print-Electronic","pubTypeList":{"pubType":["Clinical Trial, Phase II","Research Support, Non-U.S. Gov't","Multicenter Study","Randomized Controlled Trial","Journal Article"]},"grantsList":{"grant":[{"agency":"Steno Diabetes Center Copenhagen (SDCC)","grantId":"SDCC 3.F CMP","orderIn":0}]},"meshHeadingList":{"meshHeading":[{"majorTopic_YN":"N","descriptorName":"Humans"},{"majorTopic_YN":"Y","descriptorName":"Diabetes Mellitus, Type 2","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"DT","qualifierName":"drug therapy"}]}},{"majorTopic_YN":"N","descriptorName":"Blood Glucose"},{"majorTopic_YN":"N","descriptorName":"Hypoglycemic Agents","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"AE","qualifierName":"adverse effects"}]}},{"majorTopic_YN":"N","descriptorName":"Blood Glucose Self-Monitoring"},{"majorTopic_YN":"N","descriptorName":"Treatment Outcome"},{"majorTopic_YN":"N","descriptorName":"Double-Blind Method"},{"majorTopic_YN":"N","descriptorName":"Adult"},{"majorTopic_YN":"N","descriptorName":"Middle Aged"},{"majorTopic_YN":"N","descriptorName":"Female"},{"majorTopic_YN":"N","descriptorName":"Male"},{"majorTopic_YN":"N","descriptorName":"Glucagon-Like Peptides"},{"majorTopic_YN":"N","descriptorName":"Islet Amyloid Polypeptide","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"TU","qualifierName":"therapeutic use"}]}},{"majorTopic_YN":"Y","descriptorName":"Sodium-Glucose Transporter 2 Inhibitors","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"TU","qualifierName":"therapeutic use"}]}},{"majorTopic_YN":"N","descriptorName":"Semaglutide"}]},"chemicalList":{"chemical":[{"name":"Blood Glucose","registryNumber":"0"},{"name":"Hypoglycemic Agents","registryNumber":"0"},{"name":"Glucagon-Like Peptides","registryNumber":"62340-29-8"},{"name":"Islet Amyloid Polypeptide","registryNumber":"0"},{"name":"semaglutide","registryNumber":"53AXN4NNHX"},{"name":"Sodium-Glucose Transporter 2 Inhibitors","registryNumber":"0"},{"name":"cagrilintide","registryNumber":"AO43BIF1U8"}]},"subsetList":{"subset":[{"code":"IM","name":"Index Medicus"}]},"fullTextUrlList":{"fullTextUrl":[{"availability":"Subscription required","availabilityCode":"S","documentStyle":"doi","site":"DOI","url":"https://doi.org/10.1016/S0140-6736(23)01163-7"}]},"commentCorrectionList":{"commentCorrection":[{"source":"MED","id":"37364591","reference":"Lancet. 2023 Aug 26;402(10403):671-673. doi: 10.1016/S0140-6736(23)01291-6.","type":"Comment in","orderIn":1}]},"isOpenAccess":"N","inEPMC":"N","inPMC":"N","citedByCount":248,"hasReferences":"Y","hasTextMinedTerms":"Y","hasDbCrossReferences":"N","hasPDF":"N","hasBook":"N","hasSuppl":"N","hasLabsLinks":"Y","hasData":"Y","authMan":"N","epmcAuthMan":"N","nihAuthMan":"N","hasTMAccessionNumbers":"Y","tmAccessionTypeList":{"accessionType":["nct"]},"dateOfCompletion":"2023-08-28","dateOfCreation":"2023-06-26","dateOfRevision":"2026-01-27","electronicPublicationDate":"2023-06-23","firstPublicationDate":"2023-06-23","firstIndexDate":"2023-06-28","hasEvaluations":"N"}]}}